EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
X Gu, Q Zhang, YB Chu, YY Zhao, YJ Zhang, D Kuo… - Lung Cancer, 2019 - Elsevier
Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China
R You, J Liu, DBC Wu, XY Qian, B Lyu… - Cancer management …, 2019 - Taylor & Francis
Objective The purpose of this study was to evaluate the cost-effectiveness of the combined
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung …
PT Tan, MIA Aziz, F Pearce, WT Lim, DBC Wu, K Ng - BMC cancer, 2018 - Springer
Background Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
[HTML][HTML] Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non–small cell lung cancers
C Chouaid, L Luciani, K LeLay, P Do… - Journal of thoracic …, 2017 - Elsevier
Abstract Introduction The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
Real-world outcomes of first-and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small …
WW Ng, CC Lin, CY Cheng, JS Jiang, SJ Kao, DY Yeh - Plos one, 2021 - journals.plos.org
The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
相关搜索
- afatinib erlotinib and gefitinib
- cost effectiveness egfr mutations
- cost effectiveness lung cancer
- use of afatinib lung cancer
- cost effectiveness use of afatinib
- patients with nsclc egfr mutations
- gemcitabine cisplatin lung cancer
- cost effectiveness patients with nsclc
- mutation testing lung cancer
- cost effectiveness gemcitabine cisplatin
- meta analysis egfr tyrosine
- treatment for patients egfr mutations
- asian patients egfr mutation
- cost effectiveness mutation testing
- cost effectiveness treatment for patients